Read this company snapshot
Daily valuation snapshot
Outlook Therapeutics, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $0.6
- Market capitalization (USD)
- $145,800,740.09
- Price / earnings (TTM)
- Not reported
- Price / book
- Not reported
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research OTLK in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research OTLK in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing OTLK with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $0.6 |
| Market capitalization (USD) | $145,800,740.09 |
| Price / earnings (TTM) | Not reported |
| Price / book | Not reported |
No matching rows. Clear the filter to see all records.
Read OTLK's valuation metrics
Company size
Outlook Therapeutics, Inc. Common Stock's recorded market capitalization is $145,800,740.09. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
Price-to-book compares market equity value with recorded book equity. Intangible assets, profitability and the company's business affect how useful the comparison is.
Research Outlook Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about OTLK. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow OTLK's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.